According to Zacks, “J&J’s Pharma segment is performing well despite challenges like generic competition for a few products, currency impact and lower HCV revenues. Contribution from new as well as core products, share buybacks and the restructuring initiative should help drive results. We believe J&J’s diversified business model, deep pipeline, lack of cyclicality and strong financial position will continue helping the company pave its way through tough situations. We expect the company to continue pursuing bolt-on acquisitions and deals to boost its portfolio. J&J has a deep and promising pipeline with a good new product launch record. However, challenges for the company remain in the form of generic competition, pricing pressure and pipeline setbacks. “
A number of other research analysts have also commented on JNJ. BTIG Research reiterated a neutral rating on shares of Johnson & Johnson in a research report on Friday, June 3rd. Leerink Swann reiterated a buy rating on shares of Johnson & Johnson in a research report on Sunday, September 11th. Wells Fargo & Co. reiterated a buy rating on shares of Johnson & Johnson in a research report on Monday, June 6th. BMO Capital Markets reiterated an outperform rating and issued a $132.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Jefferies Group increased their price target on Johnson & Johnson from $113.00 to $119.00 and gave the company a hold rating in a research note on Thursday, August 4th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and ten have issued a buy rating to the company. The company has an average rating of Hold and an average price target of $120.19.
Johnson & Johnson (NYSE:JNJ) opened at 118.81 on Tuesday. The stock has a market cap of $325.05 billion, a P/E ratio of 22.14 and a beta of 0.61. The firm has a 50-day moving average price of $119.99 and a 200-day moving average price of $116.25. Johnson & Johnson has a 52 week low of $89.90 and a 52 week high of $126.07.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 19th. The company reported $1.74 EPS for the quarter, beating the Zacks’ consensus estimate of $1.68 by $0.06. The firm had revenue of $18.50 billion for the quarter, compared to analyst estimates of $17.98 billion. Johnson & Johnson had a return on equity of 24.70% and a net margin of 20.97%. On average, equities research analysts predict that Johnson & Johnson will post $6.69 EPS for the current year.
The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 2.69%. The ex-dividend date was Friday, August 19th. Johnson & Johnson’s payout ratio is currently 60.15%.
In related news, VP Dominic J. Caruso sold 41,146 shares of Johnson & Johnson stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $125.01, for a total transaction of $5,143,661.46. Following the completion of the transaction, the vice president now owns 157,819 shares in the company, valued at $19,728,953.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Ronald A. Kapusta sold 2,935 shares of Johnson & Johnson stock in a transaction dated Friday, July 22nd. The stock was sold at an average price of $125.01, for a total value of $366,904.35. Following the transaction, the chief accounting officer now owns 28,660 shares of the company’s stock, valued at approximately $3,582,786.60. The disclosure for this sale can be found here. Corporate insiders own 0.11% of the company’s stock.
A number of institutional investors have recently bought and sold shares of JNJ. Americafirst Capital Management LLC acquired a new position in Johnson & Johnson during the second quarter worth approximately $101,000. Tuttle Tactical Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $103,000. Lenox Wealth Management Inc. boosted its stake in shares of Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the company’s stock worth $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its stake in shares of Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the company’s stock worth $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. purchased a new stake in shares of Johnson & Johnson during the second quarter worth about $127,000. Institutional investors and hedge funds own 65.32% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.